- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03301103
PTM202 and Modulation of Host Resistance to Diarrheagenic E. Coli (APA12/PANTER)
PTM202 and Modulation of Host Resistance to Diarrheagenic Escherichia Coli in a Randomized, Double-blind, Placebo Controlled Study in Healthy Human Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The APA12/PANTER study is a randomized, double-blind, placebo-controlled, parallel intervention study of 3 weeks in 72 healthy adults. The study will include 2 arms; PTM202 and placebo. Subjects will be instructed to maintain their usual pattern of physical activity and their habitual food intake, but to standardize their dietary calcium intake. After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14).
At study day 14, 15 and 16 subjects will receive either placebo or PTM202, a dietary formula containing dried bovine colostrum and dried whole egg.
Before and after the diarrheagenic E. coli challenge an online diary will be kept to record information on stool consistency, frequency, severity of symptoms and mediation intake. At various time points before and after diarrheagenic E. coli challenge stool samples will be collected. The main study parameters are Stool consistency (Bristol Stool Scale reported by the subjects in the online diary, and Percentage of fecal wet weight (% determined by freeze-drying).
Secondary study parameters are: Stool frequency (Stools per day reported by the subjects in the online diary), Total fecal wet weight (fecal weight in g/day), and the incidence and severity of Gastro-intestinal symptoms (Gastro-intestinal Symptom Rating Scale reported by the subjects in the online diary).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Gelderland
-
Ede, Gelderland, Netherlands, 6718ZB
- NIZO
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male;
- Age between 18 and 55 years;
- BMI ≥18 and ≤27 kg/m2;
- Healthy as assessed by the NIZO food research medical questionnaire.
- Ability to follow verbal and written instructions;
- Availability of internet connection;
- Signed informed consent;
- Willing to accept disclosure of the financial benefit of participation in the study to the authorities concerned;
- Willing to accept use of all encoded data, including publication, and the confidential use and storage of all data for at least 15 years;
- Willing to comply with study procedures, including collection of stool samples;
- Willingness to abstain from high calcium containing products;
- Willingness to abstain from alcoholic beverages three days before, during and for four days after diarrheagenic E. coli challenge;
- Willingness to abstain from antibiotics, norit, laxatives, nonsteroidal anti-inflammatory drugs (OTC), opiates, antacids, proton pump inhibitors, and antimotility agents (e.g., loperamide) on the three days before, during and for four days after diarrheagenic E. coli challenge.
- Willingness to abstain from probiotics three days before, during and for four days after diarrheagenic E. coli challenge;
- Willingness to give up blood donation starting 1 month prior to study start and during the entire study;
Exclusion Criteria:
- Any confirmed or suspected immunosuppressive or immunodeficient condition including human immunodeficiency virus infection (HIV);
- Disease of the GI tract, liver, bile bladder, kidney, thyroid gland (self-reported);
- Diarrheagenic E. coli strain (as used in the study) detected in fecal sample at screening;
- Evidence of current excessive alcohol consumption or non-therapeutic drug (ab)use);
- High titer serum antibodies against CFA-II diarrheagenic E. coli strain (as used in the study) at screening;
- History of microbiologically confirmed ETEC or cholera infection in last 3 years;
- Known allergy to the following antibiotics: ciprofloxacin, trimethoprim-sulfamethoxazole, and penicillins;
- Known allergy to soy, milk- and/or egg;
- Mental status that is incompatible with the proper conduct of the study;
- Occupation involving handling of ETEC or Vibrio cholerae currently, or in the past 3 years;
- Reported average stool frequency of <1 or >3 per day;
- Symptoms consistent with Travelers' Diarrhea concurrent with travel to countries where ETEC infection is endemic (most of the developing world) within 3 years prior to dosing, OR planned travel to endemic countries during the length of the study;
- Use of antibiotics, norit, laxatives (up till 6 months prior to inclusion), cholesterol lowering agents, antacids, proton pump inhibitors and immune suppressive agents (up till 3 months prior to inclusion);
- Vaccination for or ingestion of ETEC, cholera, or E coli heat labile toxin within 3 years prior to inclusion;
- Vegans.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
The placebo will consist of low-lactose isonitrogenous soy product, and will be matched in appearance and flavour to PTM202. After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14). |
After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14).
|
Experimental: PTM202
PTM202 is a dry powder for reconstitution, comprised of a proprietary mixture of dried bovine colostrum and dried whole egg. After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14). |
After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14).
PTM202 is a dietary formula containing a proprietary mixture of dried bovine colostrum and dried whole egg.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stool consistency
Time Frame: Before challenge (Day 11-13), After challenge (Day 14-18)
|
Change in stool consistency score (questionnaire) before and after E. coli challenge
|
Before challenge (Day 11-13), After challenge (Day 14-18)
|
Relative fecal wet weight
Time Frame: Before challenge (Day 11-13), After challenge (Day 14-18)
|
Change in relative fecal wet weight (freeze-drying) before and after E. coli challenge
|
Before challenge (Day 11-13), After challenge (Day 14-18)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stool frequency
Time Frame: Before challenge (Day 11-13), After challenge (Day 14-18)
|
Change in stool frequency (questionnaire) before and after E. coli challenge
|
Before challenge (Day 11-13), After challenge (Day 14-18)
|
Total fecal wet weight
Time Frame: Before challenge (Day 11-13), After challenge (Day 14-18)
|
Change in total fecal wet weight (wet weight measurement) before and after E. coli challenge
|
Before challenge (Day 11-13), After challenge (Day 14-18)
|
Gastro-intestinal symptoms
Time Frame: Before challenge (Day 11-13), After challenge (Day 14-18)
|
Change in gastro-intestinal symptoms (questionnaire) before and after E. coli challenge
|
Before challenge (Day 11-13), After challenge (Day 14-18)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Van Schaik, NIZO food research
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL62453.028.17
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Traveler's Diarrhea
-
Intercell USA, Inc.CompletedTraveler's DiarrheaUnited States
-
Cosmo Technologies LtdBausch Health Americas, Inc.CompletedTraveler's DiarrheaGuatemala, Mexico
-
RedHill Biopharma LimitedNot yet recruiting
-
RedHill Biopharma LimitedNot yet recruiting
-
Clasado Biosciences LtdWithdrawnTraveler's Diarrhea
-
Intercell USA, Inc.CompletedTraveler's DiarrheaIndia, United Kingdom, Germany
-
Dr. Falk Pharma GmbHCompletedTraveler's DiarrheaEcuador, Guatemala, India
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Lund UniversityCompletedTraveler's Diarrhea | Antibiotic Resistant Infection | Antibiotic Resistant StrainSweden
-
Aboca Spa Societa' AgricolaUnknownDiarrhea | Diarrhea, Infantile | Chronic Diarrhea | Acute Diarrhea
Clinical Trials on E. coli strain E1392-75-2A
-
NIZO Food ResearchFrieslandCampinaCompleted
-
NIZO Food ResearchCompletedGastroenteritis | Diarrhea | Bacterial Infections | Escherichia Coli InfectionsNetherlands
-
Scandinavian Biopharma ABJohns Hopkins Bloomberg School of Public HealthRecruitingETEC DiarrheaUnited States
-
Weill Medical College of Cornell UniversityBioBalance CorporationCompletedIrritable Bowel Syndrome (IBS)United States
-
Johns Hopkins Bloomberg School of Public HealthPATH Vaccine SolutionsCompleted
-
Ardeypharm GmbHICON plc; Clinscience Sp. z o.o.Completed
-
HealthCore-NERINational Heart, Lung, and Blood Institute (NHLBI)CompletedHepatitis C | ThalassemiaUnited States, United Kingdom, Canada
-
PATHWithdrawnShigella Sonnei DysenteriesUnited States
-
International Vaccine InstituteBill and Melinda Gates Foundation; Thrasher Research Fund; Open PhilanthropyNot yet recruiting
-
Washington University School of MedicineBarnes-Jewish HospitalCompleted